Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Biomedical and Environmental Sciences ; (12): 161-166, 2010.
Artículo en Inglés | WPRIM | ID: wpr-360608

RESUMEN

<p><b>OBJECTIVE</b>To investigate the protective effects of putative AGEs (advanced glycation endproducts) inhibitor salidroside against aging in an accelerated mouse aging model induced by D-galactose.</p><p><b>METHODS</b>A group of 5-month-old C57BL/6J mice were treated daily with D-galactose, D-galactose combined with salidroside, salidroside alone, and control buffer for 8 weeks. At the end of the treatment, serum AGEs levels, neurological activities, expression of glial fibrillary acidic protein (GFAP) and neurotrophin-3 (NT-3) in the cerebral cortex, as well as lymphocyte proliferation and IL-2 production were determined.</p><p><b>RESULTS</b>D-galactose induced mouse aging model was developed as described before. As expected, salidroside blocked D-galactose induced increase of serum AGEs levels. It also reversed D-galactose induced aging effects in neural and immune system, as evidenced by improving motor activity, increasing memory latency time, and enhancing lymphocyte mitogenesis and interleukin-2 (IL-2) production. Furthermore, elevated expression of GFAP and NT-3 in the aged model mice was also reduced upon salidroside treatment.</p><p><b>CONCLUSION</b>Salidroside inhibits AGEs formation in vivo, which at least partially contributes to its anti-aging effect in D-galactose induced aging model.</p>


Asunto(s)
Animales , Ratones , Envejecimiento Prematuro , Sangre , Corteza Cerebral , Metabolismo , Medicamentos Herbarios Chinos , Farmacología , Usos Terapéuticos , Galactosa , Proteína Ácida Fibrilar de la Glía , Glucósidos , Farmacología , Usos Terapéuticos , Productos Finales de Glicación Avanzada , Sangre , Interleucina-2 , Metabolismo , Memoria , Ratones Endogámicos C57BL , Actividad Motora , Factores de Crecimiento Nervioso , Metabolismo , Proteínas del Tejido Nervioso , Metabolismo , Fenoles , Farmacología , Usos Terapéuticos , Bazo , Alergia e Inmunología , Linfocitos T
2.
Biomedical and Environmental Sciences ; (12): 212-217, 2008.
Artículo en Inglés | WPRIM | ID: wpr-296062

RESUMEN

<p><b>OBJECTIVE</b>To study whether Lycium barbarum glycopeptide 3 (LBGP3) affects T cell apoptosis in aged mice.</p><p><b>METHODS</b>LBGP3 was purified with DEAE cellulose and Sephadex columns. Apoptotic "sub-G1 peak" was detected by flow cytometry and DNA ladder was resolved by agarose gel electrophoresis. Levels of IFN-gamma and IL-10 were measured with specific kits and mRNA expression was detected by RT-PCR. Apoptosis-related proteins of FLIP, FasL, and Bcl-2 were determined by Western blotting.</p><p><b>RESULTS</b>LBGP3 was purified from Fructus Lycii water extracts and identified as a 41 kD glycopeptide. Treatment with 200 microg/mL LBGP3 increased the apoptotic rate of T cells from aged mice and showed a similar DNA ladder pattern to that in young T cells. The reversal of apoptotic resistance was involved in down-regulating the expression of Bcl-2 and FLIP, and up-regulating the expression of FasL.</p><p><b>CONCLUSION</b>Lycium barbarum glycopeptide 3 reverses apoptotic resistance of aged T cells by modulating the expression of apoptosis-related molecules.</p>


Asunto(s)
Animales , Ratones , Envejecimiento , Alergia e Inmunología , Apoptosis , Proteína Ligando Fas , Alergia e Inmunología , Glicopéptidos , Farmacología , Interferón gamma , Genética , Alergia e Inmunología , Interleucina-10 , Genética , Alergia e Inmunología , Lycium , Química , Ratones Endogámicos C57BL , Proteínas Proto-Oncogénicas c-bcl-2 , Alergia e Inmunología , ARN Mensajero , Alergia e Inmunología , Linfocitos T , Alergia e Inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA